Psychiatric Times December 24, 2024
With MM120 in phase 3 in the MindMed trial, what place do psychedelics hold in psychiatry?
In part 2 of Psychiatric Times’s interview with MindMed’s chief medical officer, Daniel R. Karlin, MD, MA, he discusses what the study might mean for the future of psychedelics in psychopharmacology and addresses some apprehensive feelings doctors might have regarding the use of psychedelics in treating patients.
Karlin told Psychiatric Times that initially there was quite a bit of interest in the potential of lysergide d-tartrate (LSD) to treat psychiatric illness.
He said the idea of using this drug and the category of drugs in this way is not new but were not utilized after being categorized as a Schedule I substance.
“Certainly it is reasonable to...
Today's Sponsors
Today's Sponsor